国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (10): 741-743.doi: 10.3760/cma.j.issn.1673-422X.2016.10.005

• 论著 • 上一篇    下一篇

华蟾素注射液联合化疗一线治疗晚期非小细胞肺癌效果分析

曹杰,周俭,杨迪,储晶   

  1. 213003 江苏省常州市中医院肿瘤科
  • 出版日期:2016-10-08 发布日期:2016-09-07
  • 通讯作者: 曹杰 E-mail:1300469652@qq.com

Clinical curative effect on nonsmall cell lung cancer patients by cinobufacini injection combined firstline chemotherapy

Cao Jie, Zhou Jian, Yang Di, Chu Jin   

  1. Department of Oncology, Changzhou Hospital of Traditional Chinese Medicine of Jiangsu Province, Changzhou 213003, China
  • Online:2016-10-08 Published:2016-09-07
  • Contact: Cao Jie E-mail:1300469652@qq.com

PDF

1410

摘要： 目的探讨华蟾素注射液联合化疗一线治疗晚期非小细胞肺癌（NSCLC）的临床效果。方法选取2013年1月至2015年1月于我院接受治疗的80例晚期NSCLC患者为研究对象。运用随机数字表法将其均分为观察组（n=40）和对照组（n=40）。对照组采用多西他赛与顺铂联合化疗方案。观察组在对照组基础上加用华蟾素注射液。比较两组患者疾病控制率、不良反应情况及其预后。结果观察组疾病控制率为77.5%，对照组为62.5%，观察组疾病控制率明显高于对照组（χ2=5.36，P=0.03）。观察组不良反应中白细胞下降发生率明显低于对照组（27.5%∶50.0%），差异有统计学意义（χ2=4.27，P=0.04），而腹泻、腹痛、呕吐、耳鸣发生率差异无统计学意义（17.5%∶27.5%, χ2=1.15， P=0.28； 25.0%∶45.0%, χ2=3.52， P=0.06;5.0%∶7.5%, χ2=0.34， P=0.56； 7.5%∶10.0%, χ2=0.16， P=0.69）。观察组和对照组患者中位生存时间分别为97 d、45 d，差异有统计学意义(HR=8.934， χ2=9.928， P＜0.05）。结论华蟾素注射液联合多西他赛能有效降低骨髓抑制发生率，提高疾病控制率，治疗安全性高，临床效果显著，可改善患者的预后。

关键词: 癌, 非小细胞肺, 紫杉烷类, 华蟾素注射液

Abstract: ObjectiveTo explore the clinical curative effect on nonsmall cell lung cancer (NSCLC) patients by cinobufacini injection combined with firstline chemotherapy. MethodsEighty patients with NSCLC from January 2013 to January 2015 in our hospital were selected as the research objects. Then they were divided into the observation group (n=40) and the control group (n=40) by random number tables. The patients in control group accepted docetaxel and cisplatin combination chemotherapy regimens (TP). While the observation group accepted cinobufacini injection on the basis of the control group. Then the local control, adverse reactions and prognosis of the two groups were compared. ResultsThe local control of observation group was 77.5%, while the control group was 62.5%, the local control of observation group was obviously higher than that of the control group (χ2=5.36, P=0.03). Leucopenia incidence of the observation group was 27.5%, the control group was 50.0%, and the incidence of the observation group was obviously lower than that of the control group (χ2=4.27, P=0.04). There was no statistically significant difference between the two groups in diarrhea, stomachache, vomiting, tinnitus (17.5% vs. 27.5%, χ2=1.15， P=0.28； 25.0% vs. 45.0%, χ2=3.52， P=0.06;  5.0% vs. 7.5%, χ2=0.34， P=0.56； 7.5% vs. 10.0%, χ2=0.16， P=0.69). There was statistically significant difference between the two groups in median survival time (97 d vs. 45 d, HR=8.934, χ2=9.928, P＜0.05). ConclusionThe cinobufacini injection combined with docetaxel can effectively reduce the incidence of myelosuppression, and improve survival and local control with high safety, and the clinical effect is remarkable and can improve the prognosis of patients.

Key words: Carcinoma, nonsmall cell lung, Taxoids, Cinobufacini injection